IDEX Corporation Q4 Earnings Call Highlights: HST Segment Leads the Way with Record Orders and Margin Expansion

IDEX Corporation reported Q4 earnings with record $493 million in orders for Health & Science Technologies, driving organic revenue growth and margin expansion. Total company organic revenue grew 1%, with adjusted EBITDA margin up ~40 bps. Free cash flow reached $617 million, and the company returned capital via buybacks, dividends, and reduced gross leverage. For fiscal 2026, management guided modest organic growth of 1–2%, adjusted EBITDA margin of 26.5–27%, and adjusted EPS of $8.15–$8.35.